Experimental nanoparticle boosts radiation against esophageal cancer

NCT ID NCT04615013

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 4 times

Summary

This early-phase trial tests a new drug called NBTXR3, which is injected into the tumor and activated by radiation to destroy cancer cells. It is given alongside standard chemotherapy for people with stage II–III esophageal adenocarcinoma. The main goals are to find the safest dose and see if the combination is tolerable. Only 24 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NBTXR3 (a nanoparticle drug activated by radiation)
What this could lead to
If it works, this could point toward a new way to enhance radiation and chemotherapy for esophageal cancer, potentially improving tumor control.
What could go wrong
This is a very early Phase 1 trial with only 24 participants, focused on safety and dosing. It may not lead to a proven treatment, and side effects from the combination therapy are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL ESOPHAGUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.